- Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
- Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
- Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
- Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
Key statistics
On Friday, Ryvu Therapeutics SA (RVU:WSE) closed at 49.50, 5.32% above its 52-week low of 47.00, set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 50.20 |
---|---|
High | 50.30 |
Low | 49.25 |
Bid | 49.25 |
Offer | 49.50 |
Previous close | 49.50 |
Average volume | 2.35k |
---|---|
Shares outstanding | 23.12m |
Free float | 14.97m |
P/E (TTM) | -- |
Market cap | 1.14bn PLN |
EPS (TTM) | -4.10 PLN |
Data delayed at least 15 minutes, as of Jul 05 2024.
More ▼